The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children
Open accessAbstract
IMPORTANCE: Type 1 diabetes usually has a preclinical phase identified by circulating islet autoantibodies, but the rate of progression to diabetes after seroconversion to islet autoantibodies is uncertain. OBJECTIVE: To determine the rate of progression to diabetes after islet autoantibody seroconversion. DESIGN, SETTING, AND PARTICIPANTS: Data were pooled from prospective cohort studies performed in Colorado (recruitment, 1993-2006), Finland (recruitment, 1994-2009), and Germany (recruitment, 1989-2006) examining children genetically at risk for type 1 diabetes for the development of insulin autoantibodies, glutamic acid decarboxylase 65 (GAD65) autoantibodies, insulinoma antigen 2 (IA2) autoantibodies, and diabetes. Participants were all children recruited and followed up in the 3 studies (Colorado, 1962; Finland, 8597; Germany, 2818). Follow-up assessment in each study was concluded by July 2012. MAIN OUTCOMES AND MEASURES: The primary analysis was the diagnosis of type 1 diabetes in children with 2 or more autoantibodies. The secondary analysis was the diagnosis of type 1 diabetes in children with 1 autoantibody or no autoantibodies. RESULTS: Progression to type 1 diabetes at 10-year follow-up after islet autoantibody seroconversion in 585 children with multiple islet autoantibodies was 69.7% (95% CI, 65.1%-74.3%), and in 474 children with a single islet autoantibody was 14.5% (95% CI, 10.3%-18.7%). Risk of diabetes in children who had no islet autoantibodies was 0.4% (95% CI, 0.2%-0.6%) by the age of 15 years. Progression to type 1 diabetes in the children with multiple islet autoantibodies was faster for children who had islet autoantibody seroconversion younger than age 3 years (hazard ratio [HR], 1.65 [95% CI, 1.30-2.09; P < .001]; 10-year risk, 74.9% [95% CI, 69.7%-80.1%]) vs children 3 years or older (60.9% [95% CI, 51.5%-70.3%]); for children with the human leukocyte antigen (HLA) genotype DR3/DR4-DQ8 (HR, 1.35 [95% CI, 1.09-1.68; P = .007]; 10-year risk, 76.6% [95% CI, 69.2%-84%]) vs other HLA genotypes (66.2% [95% CI, 60.2%-72.2%]); and for girls (HR, 1.28 [95% CI, 1.04-1.58; P = .02];10-year risk, 74.8% [95% CI, 68.0%-81.6%]) vs boys (65.7% [95% CI, 59.3%-72.1%]). CONCLUSIONS AND RELEVANCE: The majority of children at risk of type 1 diabetes who had multiple islet autoantibody seroconversion progressed to diabetes over the next 15 years. Future prevention studies should focus on this high-risk population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The presence of multiple islet autoantibodies (IAA, GADA, IA-2A/IA-2bA, or ZnT8A) is associated with a risk of type 1 diabetes of >90% (408,422,423).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most people with a single autoantibody do not progress to type 1 diabetes, but seroconversion to the presence of two or more serum autoantibodies in children is associated with an 84% risk of clinical type 1 diabetes by the age of 18 years (figure 2A).16”
From Type 1 diabetes (2018) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because of the low prevalence of type 1 diabetes (approximately 0.3% in the general population), the positive predictive value of a single islet autoantibody is low (408).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most individuals without diabetes who have only one autoantibody will not develop type 1 diabetes, as the 10-year risk is about 15% (408).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is clear from prospective studies that the persistent presence of two or more islet autoantibodies is a nearcertain predictor of clinical diabetes (42).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [42]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of the 585 children who developed more than two autoantibodies, nearly 70% developed type 1 diabetes within 10 years and 84% within 15 years (42).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is clear from prospective studies that the persistent presence of two or more islet autoantibodies is a near-certain predictor of clinical diabetes (40).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of the 585 children who developed more than two autoantibodies, nearly 70% developed type 1 diabetes within 10 years and 84% within 15 years (40).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A seminal analysis of four different birth cohorts from the USA, Finland and Germany demonstrated that the presence of a single islet autoantibody is associated with a 13% risk of developing type 1 diabetes over 15 years. In contrast, having two or more antibodies is associated with a 70% risk over 10 years of observation and an 84% risk over 15 years63.”
From 100 years of insulin: celebrating the past, present and future of diabetes therapy (2021) · cites this paper as [63]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, studies of the offspring of people with diabetes show that young children with multiple autoantibodies develop diabetes during childhood [ 12 ]”
From Islet autoantibody profiles associated with higher diabetes risk in Lithuanian compared with English schoolchildren (2020) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“In children with only one persistent islet autoantibody, the risk of diabetes within 10 years is 15% while two or more islet autoantibodies predict type 1 diabetes in 70% within 10 years (408,409).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eisenbarth (1986) · doi:10.1056/nejm198605223142106 · Cited by 1,659
Self-citationEffects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Ziegler, A., Hummel, M., Schenker, M., & Bonifacio, E. E. (1999) · Diabetes · doi:10.2337/diabetes.48.3.460 · Cited by 640
Self-citationGale, E. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15786-3 · Cited by 534
Rewers, M., Bugawan, T. L., Norris, J. M., Blair, A., Beaty, B., Hoffman, M., McDuffie, R. S., Hamman, R. F., Klingensmith, G., Eisenbarth, G. S., et al. (1996) · Diabetologia · doi:10.1007/s001250050514 · Cited by 422
Self-citationNäntö-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T., Hekkala, A., Korhonen, S., Erkkola, R., Sipilä, J. I., Haavisto, L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61309-4 · Cited by 382
Self-citationQuantification of islet-cell antibodies and prediction of insulin-dependent diabetes
Bonifacio, E. E., Shattock, M., Dean, B. M., Bottazzo, G. F., Bingley, P. J., Gale, E., & Dunger, D. B. (1990) · The Lancet · doi:10.1016/0140-6736(90)90013-u · Cited by 344
Self-citationStratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics
Achenbach, P., Warncke, K., Reiter, J., Naserke, H. E., Williams, A. J. K., Bingley, P. J., Bonifacio, E. E., & Ziegler, A. (2004) · Diabetes · doi:10.2337/diabetes.53.2.384 · Cited by 276
Self-citationOrban, T., Sosenko, J. M., Cuthbertson, D., Krischer, J. P., Skyler, J. S., Jackson, R., Yu, L., Palmer, J. P., Schatz, D., Eisenbarth, G., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0934 · Cited by 260
Self-citationPREDICTING INSULIN-DEPENDENT DIABETES
Tarn, A., Dean, B., Schwarz, G., Thomas, J. M., Ingram, D., Bottazzo, G. F., & Gale, E. M. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91601-7 · Cited by 260
Cited by
Sorted by citations
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019
(2018) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,855
2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D. M., et al. (2022) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,841
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s002 · Cited by 2,086
(2) Classification and diagnosis of diabetes
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s005 · Cited by 1,841
2. Classification and Diagnosis of Diabetes
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s005 · Cited by 1,603
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31320-5 · Cited by 1,561
Katsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B. J., Jacobsen, L. M., Schatz, D. A., & Lernmark, Å. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.16 · Cited by 1,475
Self-citation2. Diagnosis and classification of diabetes: standards of care in diabetes-2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s002 · Cited by 1,393
Insel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Krischer, J. P., Lernmark, Å., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1419 · Cited by 1,216
Self-citationKostic, A. D., Gevers, D., Siljander, H., Vatanen, T., Hyötyläinen, T., Hämäläinen, A., Peet, A., Tillmann, V., Pöhö, P., Mattila, I. M., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.01.001 · Cited by 1,198
Self-citation2. Classification and Diagnosis of Diabetes
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s005 · Cited by 1,116
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 1,039
Definition, Classification and Diagnosis of Diabetes Mellitus
Kerner, W., & Brückel, J. (2014) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0034-1366278 · Cited by 897
Differentiation of diabetes by pathophysiology, natural history, and prognosis
Skyler, J. S., Bakris, G. L., Bonifacio, E., Darsow, T., Eckel, R. H., Groop, L., Groop, P.-H., Handelsman, Y., Insel, R. A., Mathieu, C., et al. (2017) · Diabetes · doi:10.2337/db16-0806 · Cited by 823
Self-citationMayer‐Davis, E. J., Kahkoska, A. R., Jefferies, C., Dabelea, D., Balde, N. M., Gong, C., Aschner, P. J., & Craig, M. E. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12773 · Cited by 718
Environmental risk factors for type 1 diabetes
Rewers, M., & Ludvigsson, J. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30507-4 · Cited by 676
Self-citationDefinition, Classification and Diagnosis of Diabetes Mellitus
Petersmann, A., Müller‐Wieland, D., Müller, U., Landgraf, R., Nauck, M. A., Freckmann, G., Heinemann, L., & Schleicher, E. D. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9078 · Cited by 630
Genetic risk factors for type 1 diabetes
Pociot, F., & Lernmark, Å. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30582-7 · Cited by 553
The heterogeneous pathogenesis of type 1 diabetes mellitus
Ilonen, J., Lempainen, J., & Veijola, R. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0254-y · Cited by 522
Self-citationChen, C., Cohrs, C. M., Stertmann, J., Bozsak, R., & Speier, S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.019 · Cited by 506
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s002 · Cited by 473
the TEDDY Study Group, Krischer, J. P., Lynch, K. F., Schatz, D. A., Ilonen, J., Lernmark, Å., Hagopian, W. A., Rewers, M. J., She, J.-X., Simell, O. G., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3514-y · Cited by 444
Self-citationChung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetes Care · doi:10.2337/dci20-0022 · Cited by 400
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Sims, E. K., Bundy, B. N., Stier, K., Serti, E., Lim, N., Long, S. A., Geyer, S. M., Moran, A., Greenbaum, C. J., Evans-Molina, C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8980 · Cited by 377
Self-citationType 1 diabetes—early life origins and changing epidemiology
Norris, J. M., Johnson, R. K., & Stene, L. C. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30412-7 · Cited by 378
Sharp, S. A., Rich, S. S., Wood, A. R., Jones, S. E., Beaumont, R. N., Harrison, J. W., Schneider, D. A., Locke, J. M., Tyrrell, J., Weedon, M. N., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1785 · Cited by 366
Definition, epidemiology, and classification of diabetes in children and adolescents
Craig, M. E., Jefferies, C., Dabelea, D., Balde, N. M., Seth, A., & Donaghue, K. C. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12186 · Cited by 399
Autoreactive T cells in type 1 diabetes
Pugliese, A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94549 · Cited by 365
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
Battaglia, M., Ahmed, S., Anderson, M. S., Atkinson, M. A., Becker, D., Bingley, P. J., Bosi, E., Brusko, T. M., DiMeglio, L. A., Evans-Molina, C., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0880 · Cited by 351
Self-citationFerreira, R. C., Guo, H., Coulson, R., Smyth, D. J., Pękalski, M. Ł., Burren, O. S., Cutler, A. J., Doecke, J. D., Flint, S. M., McKinney, E. F., et al. (2014) · Diabetes · doi:10.2337/db13-1777 · Cited by 323
Self-citationYield of a public health screening of children for islet autoantibodies in Bavaria, Germany
Ziegler, A.-G., Kick, K., Bonifacio, E., Haupt, F., Hippich, M., Dunstheimer, D., Lang, M., Laub, O., Warncke, K., Lange, K., et al. (2020) · JAMA · doi:10.1001/jama.2019.21565 · Cited by 312
Self-citationMetabolite-Sensing G Protein–Coupled Receptors—Facilitators of Diet-Related Immune Regulation
Tan, J. K., McKenzie, C. I., Mariño, E., Macia, L., & Mackay, C. R. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052235 · Cited by 305
Diabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans‐Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Suszták, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 350
The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes
Pearson, J. A., Wong, F. S., & Li, W. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.08.019 · Cited by 320
Libman, I. M., Haynes, A., Lyons, S. K., Pradeep, P., Rwagasor, E., Tung, J. Y., Jefferies, C., Oram, R. A., Dabelea, D., & Craig, M. E. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13454 · Cited by 339
AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies
Meyer, S., Woodward, M., Hertel, C. B., Vlaicu, P., Haque, Y., Kärner, J., Macagno, A., Onuoha, S. C., Fishman, D., Peterson, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.024 · Cited by 303
Viral infections in type 1 diabetes mellitus — why the β cells?
Op de Beeck, A., & Eizirik, D. L. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.30 · Cited by 291
100 years of insulin: celebrating the past, present and future of diabetes therapy
Sims, E. K., Carr, A. L. J., Oram, R. A., DiMeglio, L. A., & Evans-Molina, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01418-2 · Cited by 270
Metabolomics of type 1 and type 2 diabetes
Arneth, B., Arneth, R., & Shams, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102467 · Cited by 262
New frontiers in the treatment of type 1 diabetes
Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259
Mechanisms and consequences of sex differences in immune responses
Dunn, S. E., Perry, W. A., & Klein, S. L. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00787-w · Cited by 269
Adult-Onset Type 1 Diabetes: Current Understanding and Challenges
Leslie, R. D., Evans‐Molina, C., Freund-Brown, J., Buzzetti, R., Dabelea, D., Gillespie, K. M., Goland, R., Jones, A. G., Kacher, M. L., Phillips, L. S., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0770 · Cited by 288
Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective
Sims, E. K., Besser, R. E. J., Dayan, C. M., Rasmussen, C. G., Greenbaum, C. J., Griffin, K., Hagopian, W., Knip, M., Long, A. E., Martin, F., et al. (2022) · Diabetes · doi:10.2337/dbi20-0054 · Cited by 274
Self-citationQuattrin, T., Mastrandrea, L. D., & Walker, L. S. K. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00223-4 · Cited by 292
Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes Predicts Poor Long-term Glycemic Control
Duca, L. M., Wang, B., Rewers, M., & Rewers, A. (2017) · Diabetes Care · doi:10.2337/dc17-0558 · Cited by 241
Self-citationA 3D map of the islet routes throughout the healthy human pancreas
Ionescu-Tirgoviste, C., Gagniuc, P. A., Gagniuc, E., Mardare, L., Popescu, I., Dima, S., & Militaru, M. (2015) · Scientific Reports · doi:10.1038/srep14634 · Cited by 251
Fasolino, M., Schwartz, G. W., Patil, A. R., Mongia, A., Golson, M. L., Wang, Y. J., Morgan, A. R., Liu, C., Schug, J., Liu, J., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00531-x · Cited by 225
The immunology of type 1 diabetes
Herold, K. C., Delong, T., Perdigoto, A. L., Biru, N., Brusko, T. M., & Walker, L. S. K. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-023-00985-4 · Cited by 241
Pullano, S. A., Greco, M., Bianco, M. G., Foti, D., Brunetti, A., & Fiorillo, A. S. (2022) · Theranostics · doi:10.7150/thno.64035 · Cited by 210
“Insulin-dependent type 1 diabetes accounts for about 5-10 % of all cases of diabetes, and is characterized by a failure in insulin production for an autoimmune attack on pancreatic beta cells [24,25].”
BackgroundChung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05181-w · Cited by 203
Effects of High-Dose Oral Insulin on Immune Responses in Children at High Risk for Type 1 Diabetes
Bonifacio, E. E., Ziegler, A., KLINGENSMITH, G. J., Schober, E., Bingley, P. J., Rottenkolber, M., Theil, A., Eugster, A., Puff, R., Peplow, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.2928 · Cited by 198
Self-citationEarly prediction of autoimmune (type 1) diabetes.
Regnell, S. E., & Lernmark, Å. (2017) · Diabetologia · doi:10.1007/s00125-017-4308-1 · Cited by 195
Perinatal tolerance to proinsulin is sufficient to prevent autoimmune diabetes
Jhala, G., Chee, J., Trivedi, P., Selck, C., Gurzov, E. N., Graham, K. L., Thomas, H. E., Kay, T. W. H., & Krishnamurthy, B. (2016) · JCI Insight · doi:10.1172/jci.insight.86065 · Cited by 196
Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes
Michels, A. W., Landry, L. G., McDaniel, K. A., Yu, L., Campbell‐Thompson, M., Kwok, W. W., Jones, K. L., Gottlieb, P. A., Kappler, J. W., Tang, Q., et al. (2016) · Diabetes · doi:10.2337/db16-1025 · Cited by 198
Predicting Type 1 Diabetes Using Biomarkers
Bonifacio, E. E. (2015) · Diabetes Care · doi:10.2337/dc15-0101 · Cited by 191
Self-citationKallionpää, H., Elo, L. L., Laajala, E., Mykkänen, J., Ricaño-Ponce, I., Vaarma, M., Laajala, T. D., Hyöty, H., Ilonen, J., Veijola, R., et al. (2014) · Diabetes · doi:10.2337/db13-1775 · Cited by 187
Self-citationSteck, A. K., Vehik, K., Bonifacio, E., Lernmark, A., Ziegler, A.-G., Hagopian, W. A., She, J., Simell, O., Akolkar, B., Krischer, J., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2426 · Cited by 185
Self-citationKrischer, J. P., Lynch, K. F., Lernmark, Å., Hagopian, W., Rewers, M., She, J., Toppari, J., Ziegler, A., Akolkar, B., & the TEDDY Study Group (2017) · Diabetes Care · doi:10.2337/dc17-0238 · Cited by 189
Self-citationCD4 T cell differentiation in type 1 diabetes
Walker, L. S. K., & von Herrath, M. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12672 · Cited by 189
Definition, Klassifikation und Diagnostik des Diabetes mellitus
Nauck, M. A., Petermann, A., Müller‐Wieland, D., Kerner, W., Müller, U., Landgraf, R., Freckmann, G., & Heinemann, L. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-115953 · Cited by 178
Compromised Gut Microbiota Networks in Children With Anti-Islet Cell Autoimmunity
Endesfelder, D., zu Castell, W., Ardissone, A. N., Davis‐Richardson, A. G., Achenbach, P., Hagen, M., Pflueger, M., Gano, K. A., Fagen, J. R., Drew, J. C., et al. (2014) · Diabetes · doi:10.2337/db13-1676 · Cited by 176
Self-citationSeyhan, A. A., López, Y. O. N., Xie, H., Yi, F., Mathews, C. E., Pasarica, M., & Pratley, R. E. (2016) · Scientific Reports · doi:10.1038/srep31479 · Cited by 178
Heterogeneity and endotypes in type 1 diabetes mellitus
REDONDO, M. J., & Morgan, N. G. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00853-0 · Cited by 182
Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era
Akil, A. A., Yassin, E., Al-Maraghi, A., ALIYEV, E. E., Al-Malki, K., & Fakhro, K. A. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02778-6 · Cited by 217
Hydrolyzed Infant Formula and Early β-Cell Autoimmunity
Knip, M., Åkerblom, H. K., BECKER, D. J., Dosch, H.-M., Dupre, J., Fraser, W. D., Howard, N. J., Ilonen, J., Krischer, J. P., Kordonouri, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.5610 · Cited by 175
Self-citationAssmann, T. S., Recamonde‐Mendoza, M., de Souza, B. M., & Crispim, D. (2017) · Endocrine Connections · doi:10.1530/ec-17-0248 · Cited by 158
Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes
Writing Group for the TRIGR Study Group, Knip, M., Åkerblom, H. K., El‐Lababidi, E., BECKER, D. J., Bruining, J., Castaño, L. A., Danne, T., de Beaufort, C. E., Dosch, H., et al. (2018) · JAMA · doi:10.1001/jama.2017.19826 · Cited by 162
Self-citationType 1 diabetes mellitus: much progress, many opportunities
Powers, A. C. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142242 · Cited by 172
Sacks, D. B., Arnold, M. A., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad080 · Cited by 164
Haller, M. J., Bell, K. J., Besser, R. E. J., Casteels, K., Couper, J. J., Craig, M. E., Elding Larsson, H., Jacobsen, L., Lange, K., Oron, T., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543035 · Cited by 151
Self-citationZakharov, P. N., Hu, H., Wan, X., & Unanue, E. R. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20192362 · Cited by 149
Bonifacio, E., Beyerlein, A., Hippich, M., Winkler, C., Vehik, K., Weedon, M. N., Laimighofer, M., Hattersley, A. T., Krumsiek, J., Frohnert, B. I., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002548 · Cited by 148
Self-citationA combined risk score enhances prediction of type 1 diabetes among susceptible children
Ferrat, L. A., Vehik, K., Sharp, S. A., Lernmark, Å., Rewers, M. J., She, J.-X., Ziegler, A.-G., Toppari, J., Akolkar, B., Krischer, J. P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0930-4 · Cited by 148
Self-citationAssociated autoimmune diseases in children and adolescents with type 1 diabetes mellitus (T1DM)
Kakleas, K., Soldatou, A., Karachaliou, F., & Karavanaki, K. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.05.002 · Cited by 150
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2025
ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Early, K. B., Bruemmer, D., Ebekozien, O. A., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2024) · Diabetes Care · doi:10.2337/dc25-s003 · Cited by 171
Besser, R. E. J., Bell, K. J., Couper, J., Ziegler, A., Wherrett, D. K., Knip, M., Speake, C., Casteels, K., Driscoll, K. A., Jacobsen, L. M., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13410 · Cited by 161
Self-citation3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2024
ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s003 · Cited by 157
Couper, J., Haller, M. J., Greenbaum, C. J., Ziegler, A., Wherrett, D. K., Knip, M., & Craig, M. E. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12734 · Cited by 153
Self-citationRaab, J., Haupt, F., Scholz, M., Matzke, C., Warncke, K., Lange, K., Assfalg, R., Weininger, K., Wittich, S., Löbner, S., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011144 · Cited by 145
Self-citationMa, W.-T., Chang, C. C.-C., Gershwin, M. E., & Lian, Z. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.07.003 · Cited by 146
Cost and cost-effectiveness of large-scale screening for type 1 diabetes in Colorado
McQueen, R. B., Geno Rasmussen, C., Waugh, K., Frohnert, B. I., Steck, A. K., Yu, L., Baxter, J., & Rewers, M. (2020) · Diabetes Care · doi:10.2337/dc19-2003 · Cited by 138
Self-citationAtkinson, M. A., & Mirmira, R. G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.018 · Cited by 139
Adverse Events Associated with Immune Checkpoint Blockade
Tervaert, J.-W. C., Ye, C., & Yacyshyn, E. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1801663 · Cited by 134
Jacobsen, L. M., Bocchino, L., Evans-Molina, C., DiMeglio, L., Goland, R., Wilson, D. M., Atkinson, M. A., Aye, T., Russell, W. E., Wentworth, J. M., et al. (2020) · Diabetologia · doi:10.1007/s00125-019-05047-w · Cited by 133
Krischer, J., Liu, X., Lernmark, Å., Hagopian, W., Rewers, M., She, J., Toppari, J., Ziegler, A., & Akolkar, B. (2017) · Diabetes · doi:10.2337/db17-0261 · Cited by 108
Self-citationAnti-Islet Autoantibodies in Type 1 Diabetes
Kawasaki, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210012 · Cited by 147
Diet, Microbiota and Immune System in Type 1 Diabetes Development and Evolution
Mejía-León, M., & Barca, A. (2015) · Nutrients · doi:10.3390/nu7115461 · Cited by 125
Altered N‐glycosylation profiles as potential biomarkers and drug targets in diabetes
Rudman, N., Gornik, O., & Lauc, G. (2019) · FEBS Letters · doi:10.1002/1873-3468.13495 · Cited by 130
Frazzei, G., van Vollenhoven, R., de Jong, B. A., Siegelaar, S. E., & van Schaardenburg, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.899372 · Cited by 137
Type 1 diabetes vaccine candidates promote human Foxp3+Treg induction in humanized mice
Serr, I., Fürst, R. W., Achenbach, P., Scherm, M. G., Gökmen, F., Haupt, F., Sedlmeier, E., Knopff, A., Shultz, L. D., Willis, R. A., et al. (2016) · Nature Communications · doi:10.1038/ncomms10991 · Cited by 124
Self-citationNoninvasive mapping of pancreatic inflammation in recent-onset type-1 diabetes patients
Gaglia, J. L., Harisinghani, M. G., Aganj, I., Wojtkiewicz, G. R., Hedgire, S., Benoist, C. O., Mathis, D. J., & Weissleder, R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424993112 · Cited by 123
Type 1 diabetes: A predictable disease
Simmons, K. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i3.380 · Cited by 129
Childhood adiposity and risk of type 1 diabetes: A Mendelian randomization study
Censin, J. C., Nowak, C., Cooper, N., Bergsten, P., Todd, J. A., & Fall, T. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002362 · Cited by 120
Plasma 25-Hydroxyvitamin D Concentration and Risk of Islet Autoimmunity
Norris, J. M., Lee, H., Frederiksen, B. N., Erlund, I., Uusitalo, U., Yang, J., Lernmark, Å., Simell, O., Toppari, J., Rewers, M. J., et al. (2017) · Diabetes · doi:10.2337/db17-0802 · Cited by 114
Self-citation
Metadata
- Authors
- Ziegler, A. G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., Bonifacio, E., & Eisenbarth, G. S.
- Affiliations
- TUM Klinikum (DE)
- University of Helsinki (FI)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-06-19
- Volume
- 309
- Issue
- 23
- Pages
- 2473
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC4878912
- OpenAlex
- W2095256598
- Semantic Scholar
- 5a7a8cb24a1d4a727e23b19c717a8328b3ce09d6
- Cited by
- 1,312
- References
- 29
- Citations by year
- 2026: 118 · 2025: 133 · 2024: 103 · 2023: 124 · 2022: 107 · 2021: 127 · 2020: 83 · 2019: 92 · 2018: 92 · 2017: 86 · 2016: 89 · 2015: 83 · 2014: 55 · 2013: 18
- FWCI
- 54.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Funders
- Juvenile Diabetes Research Foundation International (4‐1999‐731, 4‐2001‐435)
- Deutsche Forschungsgemeinschaft (/14-2, /14-1)
- Bundesministerium für Bildung und Forschung
- Novo Nordisk
- Lastentautien Tutkimussäätiö
- National Institutes of Health (DK32493)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK32493, R01DK032493, U01DK063821)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, islet autoantibodies, seroconversion, multiple autoantibodies, progression to diabetes, insulin autoantibodies, GAD65 antibodies, IA-2 autoantibodies, preclinical diabetes, risk prediction, age at seroconversion, islet transplantation
- MeSH terms
- Adolescent, Autoantibodies, Child, Child, Preschool, Colorado, Diabetes Mellitus, Type 1, Female, Finland, Follow-Up Studies, Genotype, Germany, Glutamate Decarboxylase, Humans, Infant, Insulin, Islets of Langerhans, Male, Prospective Studies, Risk, Disease Progression, Genetic Predisposition to Disease, Receptor-Like Protein Tyrosine Phosphatases, Class 8
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
